Pfizer Will Struggle To Catch Novo Nordisk With Oral Obesity Treatments
Dosing Is Achilles Heel For Pfizer’s First Candidate
Novo Nordisk reasserted its dominance in the GLP-1 agonist field this week, while Pfizer must hope that one of its two shots on goal is a success.
